
An outside advisor to the U.S. Food and Drug Administration’s review of the controversial Alzheimer’s drug Aduhelm is now speaking out, arguing that the approval was based on dodgy science and involved questionable collaboration between regulators and the drug’s maker. “I’m not surprised at the controversy because I think it’s a horrible decision. I think… read on > read on >